Sodium ascorbate

Research use only, not for human use.

Sodium Ascorbate is a more bioavailable form of vitamin C that is an alternative to taking ascorbic acid as a supplement.

Ascorbate, also known as Ascorbicin, is a DNase I inhibitor. Ascorbate is an antioxidant which functions as a reducing agent and coenzyme in several metabolic pathways.(In Vitro):The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by L-Ascorbic acid sodium salt (Sodium L-ascorbate) (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5,000.(In Vivo):Tg rats treated with L-Ascorbic acid sodium salt (Sodium L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs.After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats.

The conditioned?medium?for?B16F10?cells significantly inhibits?cell?apoptosis?induced by?L-Ascorbic acid sodium salt (Sodium?L-ascorbate) (10 mM), and the effective ingredients in the?medium?show a relative molecular mass below 5,000.

Tg rats treated with L-Ascorbic acid sodium salt (Sodium?L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs. After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats.

Ascorbate | Sodium Ascorbate | Vitamin C sodium

Endocrinology/Hormones

5-HT Receptor

Others

Cancer

——

134-03-2

201.13

C6H8O6·Na

>98% (HPLC)

H2O : ≥ 41 mg/mL; 206.96 mM

[Na].[H][C@@]1(OC(=O)C(O)C1O)[C@@H](O)CO

Sodium (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-olate

(-20℃)

With Ice Pack

≥ 2 years